After ABT therapy, there was a significant reduction (p<0.05) in serum levels of ADAM17 in RA patients, although ADAM17 level in 5 patients was below a detection level (<10 pg/ml as zero value) of ELISA at both baseline and after medication (Fig. 3). Here, ADAM17 is linked to rheumatoid arthritis.